Veritas In Silico (130A) · TargetSoftened
Selection of in-house projects expected to generate annual sales of ¥20 billion or more
First written in FY2023. 1 of 2 entries say "Softened", first in FY2025. Latest entry: FY2025.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Selection of Proprietary Development Products Based on High Sales PotentialA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025SoftenedAnnual report
「If approved and commercialized, we estimate that this drug could generate domestic annual sales of approximately ¥15 billion, and we will work to have this reflected in our shareholder value as its research progresses.」
The previously stated selection criterion of annual sales of at least ¥20 billion per drug was not repeated. Instead, domestic annual sales of approximately ¥15 billion were estimated for the first p53 ASO. - FY2023First statedAnnual report
「For mRNA-targeted small-molecule drug discovery, we intend to select in-house projects expected to generate annual sales of at least ¥20 billion per drug, based on market orientation and taking advantage of the ability to apply these drugs to various diseases.」
The company set a selection criterion of annual sales of at least ¥20 billion per drug for candidates in its in-house pipeline when transitioning to the hybrid model.